2 / 18
Page 19
Notes:
allied
academies
Ann Clin Trials Vaccines Res. 2017 | Volume 1 Issue 2
Global Vaccines & Vaccination Summit & B2B
November 01-02, 2017 | Toronto, Canada
Nanoparticle-based mucosal vaccine adjuvant vectors against pandemic influenza infection
Valentina Bernasconi
1
, Beatrice Bernocchi
2
, Minh Quan Le
2
, Liang Ye
3
, Peter Staheli
3
, Karin Schon
1
, Didier Betbeder
2
and
Nils Lycke
1
1
Göteborgs Universitet, Sweden
2
Université Lille, France
3
University of Freiburg, Germany
A
vaccine against pandemic influenza infection is much
warranted. However, the formulation and design of such a
vaccine is much debated. We have developed a fusion protein
that carries the M2e-peptide that gives strong antibody and
CD4 T cell responses. The immune response to the fusion
protein CTA1-3M2e-DD provides heterosubtypic protection and
it stimulates long term memory. To expand on the possibility
to develop a stable and effective mucosal vaccine we have
combined the fusion protein with nanoparticles and have
achieved a very potent formulation. This way we can improve
targeting of nanoparticles to dendritic cells, which results in very
low reactogenicity, low antigen dose requirement and effective
immunomodulation. Furthermore, we have successfully
incorporated recombinant HA in these nanoparticles, opening
up for additional combinations with flu-relevant proteins to be
incorporated in this immunoenhancing nanoparticle complex.
Thus, we have designed a versatile candidate vaccine against
pandemic flu, which is an adjuvanted vaccine formulation with
the conservedM2e peptide and the CTA1-DD immunoenhancing
element. The combined CTA1-3M2e-DD/HA/nanoparticle
vaccine candidate is highly effective in mice and provides strong
heterosubtypic protection.
Speaker Biography
Valentina Bernasconi is 27 years old Italian PhD student currently living in Goteborg,
Sweden. She got a Bachelor and a Master degree in Medical Biotechnology at Vita-
Salute San Raffaele University, Italy, where she worked on a thesis on poxviral vectors
as universal influenza vaccines. After graduation she moved to The Netherlands to
work as a research assistant on Ebola vaccine based on adenoviral vectors. she have
then been awarded a Marie Curie Action fellowship to support my PhD studies and
she moved to Sweden, where she is currently working on the development of a
subcomponent universal mucosal vaccine against influenza virus infection based on
nanoparticles formulation.
e:
valentina.bernasconi@gu.se